CJC-1295 Dosage Guide: With DAC vs. Without DAC Protocols Explained

CJC-1295 Dosage Guide: With DAC vs. Without DAC Protocols Explained

CJC-1295 is a synthetic Growth Hormone Releasing Hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone. It is one of the most effective and widely used peptides for GH optimization, body composition, recovery, and anti-aging. Understanding the critical difference between CJC-1295 with DAC and CJC-1295 without DAC is essential before dosing, as the two formulations behave completely differently pharmacologically.

CJC-1295 With DAC vs. Without DAC: The Critical Difference

This is the most important concept in CJC-1295 dosing. The two forms are fundamentally different peptides with different dosing schedules, half-lives, and GH release patterns.

CJC-1295 Without DAC (also called Modified GRF 1-29 or Mod GRF 1-29)

Half-life: 30–45 minutes GH release pattern: Pulsatile (mimics natural GH secretion) Dosing frequency: Multiple times daily Mechanism: Binds GHRH receptors briefly, triggers one GH pulse per injection

CJC-1295 without DAC is simply a stabilized version of the natural GHRH sequence. It produces a sharp, physiological GH pulse before being cleared. This pulsatile pattern is considered more aligned with how the body naturally secretes GH and is generally preferred when stacking with a GHRP like ipamorelin.

CJC-1295 With DAC (Drug Affinity Complex)

Half-life: 6–8 days GH release pattern: Sustained "bleed" of GH over days Dosing frequency: Once weekly Mechanism: The DAC modification causes the peptide to bind to albumin in the blood, dramatically extending its half-life

CJC-1295 with DAC keeps GH levels persistently elevated rather than pulsatile. While this sounds advantageous, sustained GH elevation can increase IGF-1 disproportionately, may increase water retention, and does not replicate the natural pulsatile GH secretion pattern. Some practitioners consider it less optimal for long-term protocols.

CJC-1295 Without DAC Dosage

The standard dosage for CJC-1295 without DAC is 100–200 mcg per injection, administered 2–3 times daily.

Conservative protocol (sleep and recovery):

• 100 mcg before bed (stacked with ipamorelin)

Moderate protocol (body composition):

• 100–200 mcg 2x daily (morning fasted + before bed)

Standard research protocol:

• 100 mcg 3x daily (morning, post-workout, before bed)

CJC-1295 without DAC is almost always dosed alongside a GHRP (usually ipamorelin). The GHRH + GHRP combination produces synergistic GH release that is substantially greater than either peptide alone.

Combination injection (no-DAC + ipamorelin):

• CJC-1295 no-DAC: 100 mcg + Ipamorelin: 100–200 mcg
• Combined in one syringe, injected subcutaneously
• Administered 2–3x daily following fasting and timing guidelines

CJC-1295 With DAC Dosage

The standard dosage for CJC-1295 with DAC is 1–2 mg once per week.

Starting dose:

• 1 mg subcutaneously once weekly

Standard dose:

• 2 mg subcutaneously once weekly

High dose (advanced, supervised):

• 2 mg twice weekly (every 3–4 days)

Because CJC-1295 with DAC has a 6–8 day half-life, a single weekly injection maintains a sustained elevation of GH. Steady-state is reached after approximately 3–4 weekly injections.

Timing: CJC-1295 Without DAC

Timing is crucial for the no-DAC form because of its short half-life:

Fasting requirement: Insulin suppresses GH release at the pituitary level. Inject CJC-1295 no-DAC in a fasted state — at minimum 2 hours after eating, ideally 3 hours.

Best injection windows:

1. Before bed (primary): 15–30 minutes before sleep, 2–3 hours after last meal
2. Morning fasted: Upon waking, before breakfast
3. Post-workout (optional): 30–60 minutes after training ends

After injecting, wait 20–30 minutes before eating to allow the GH pulse to occur without insulin interference.

Timing does not matter as critically for CJC-1295 with DAC because it maintains a continuous background level regardless of meal timing.

Timing: CJC-1295 With DAC

Since CJC-1295 with DAC works over days rather than hours, specific timing within the day is less critical. However, some practitioners still inject in a fasted state to maximize the initial acute GH response at injection.

Day of week: Choose a consistent day (e.g., every Monday morning) State: Preferably fasted for initial response, though not as critical as no-DAC Rotation: Rotate injection sites (abdomen, thigh) to prevent lipohypertrophy

Cycling Protocols

CJC-1295 Without DAC Cycling

Follow the same cycling protocol as the stacked GHRP (usually ipamorelin):

• On-cycle: 8–12 weeks
• Off-cycle: 4 weeks minimum

Because no-DAC has such a short half-life, clearance after stopping is complete within hours. There is no washout period required.

CJC-1295 With DAC Cycling

The long half-life of the DAC form requires accounting for slower clearance:

• On-cycle: 8–12 weeks of weekly injections
• Off-cycle: At minimum 4–6 weeks (allow 2–3 half-lives for clearance: ~2–3 weeks for peptide, plus recovery time)

Some practitioners use CJC-1295 with DAC for 16–20 week cycles given its gentler initial impact, but extended use warrants IGF-1 monitoring.

Reconstitution and Storage

CJC-1295 no-DAC (typical vial: 2–5 mg):

• Add 2 mL bacteriostatic water to 2 mg peptide = 1 mg/mL
• Each 0.1 mL = 100 mcg
• Refrigerate; use within 28–30 days

CJC-1295 with DAC (typical vial: 2 mg):

• Add 2 mL bacteriostatic water = 1 mg/mL
• Each 0.2 mL = 200 mcg (for a 2 mg dose, draw 2 mL)
• Refrigerate; use within 28–30 days

Storage: Lyophilized (dry) peptides are stable at 2–8°C for months. Reconstituted solutions must be refrigerated and used within 30 days. Protect from light.

Which Form Should You Choose?

Choose CJC-1295 without DAC if:

• You want pulsatile, physiological GH release
• Stacking with ipamorelin or another GHRP (the most common and preferred approach)
• You prefer more control over timing
• You are new to GH peptides

Choose CJC-1295 with DAC if:

• You want less frequent injections (once weekly vs. daily)
• You are not stacking with a GHRP and want sustained baseline GH elevation
• Convenience is the primary concern
• You have experience with GH peptides and are monitoring IGF-1

The vast majority of clinical and self-experimentation protocols favor CJC-1295 no-DAC + ipamorelin as the gold standard combination.

Monitoring: IGF-1 Testing

Both forms of CJC-1295 primarily work by elevating IGF-1 via increased GH. Regular IGF-1 blood testing is recommended:

• Baseline: Before starting any protocol
• Mid-cycle (week 6–8): To assess response and confirm safe levels
• End of cycle: Final measurement before off-period

Target: IGF-1 in the upper-normal range for your age — not above the reference range. Supratherapeutic IGF-1 levels raise theoretical concerns about cell proliferation and should prompt dose reduction.

Expected Results

Weeks 1–4: Improved sleep, better recovery, mild changes in energy and mood

Weeks 4–8: Noticeable changes in body composition (lean mass gain, fat reduction — particularly subcutaneous and visceral fat), improved skin quality

Full 12-week cycle: Measurable IGF-1 elevation, significant body composition improvement, enhanced joint and connective tissue health, anti-aging skin effects

Results are dependent on diet, training, sleep, age, and baseline GH/IGF-1 status. Those with clinically low GH/IGF-1 tend to experience the most pronounced improvements.

Side Effects

CJC-1295 is generally well-tolerated. Common side effects are largely GH-mediated:

• Water retention: Particularly in early weeks as GH affects fluid balance; usually resolves
• Tingling/numbness: Carpal tunnel-like symptoms from fluid shifts; typically temporary
• Fatigue: Can occur early in a cycle; usually transient
• Headache: Dose-related; reduce dose if persistent
• Injection site reactions: Redness, mild swelling; rotate sites

With DAC form specifically: sustained GH elevation may produce more pronounced water retention and tingling compared to the pulsatile no-DAC pattern.

Frequently Asked Questions

Q: Can I mix CJC-1295 no-DAC and ipamorelin in the same syringe? Yes. Both are water-reconstituted peptides that are compatible when mixed. Draw ipamorelin first, then CJC-1295 into the same insulin syringe and inject together. This is standard practice and does not reduce efficacy of either peptide.

Q: How much GH does CJC-1295 actually raise? Research studies using CJC-1295 with DAC at 2 mg found sustained 2–10x increases in GH levels and 1.5–3x increases in IGF-1 above baseline. The exact response depends on age (younger individuals typically respond more strongly), baseline GH status, and dosing.

Q: Do I need to take a break after CJC-1295? Yes. Cycling is recommended both to allow pituitary receptor recovery and to assess whether continuing is appropriate. The 8–12 weeks on / 4 weeks off cycle is the most commonly used approach.

Q: Is CJC-1295 with DAC better than sermorelin? Sermorelin is a shorter GHRH analog (29 amino acids vs. 30 for CJC-1295) with a shorter half-life. CJC-1295 no-DAC has a similar profile to sermorelin but with slightly greater potency per injection. CJC-1295 with DAC is dramatically longer-acting than sermorelin. For pulsatile GH release, sermorelin and CJC-1295 no-DAC are comparable options; for once-weekly dosing, CJC-1295 with DAC is unique.

Q: What is the best CJC-1295 dosage for fat loss? For fat loss specifically, the most effective protocol combines CJC-1295 no-DAC with ipamorelin at 2x daily (morning fasted + before bed), maintained over 12 weeks alongside caloric optimization. Some practitioners also add AOD-9604 to the stack specifically for its lipolytic properties.

---

This article is for informational purposes only. CJC-1295 is not FDA-approved for human therapeutic use. Consult a healthcare provider before beginning any peptide protocol.